Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Meet The Professor Sessions
15:59

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

FEATURING Michael J. Mauro
  • 29 views
  • October 16, 2019
18:04

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Biomarkers To Predict Treatment Free Remission in CML – Can We Predict Who Can and Can't Stop TKI Treatment?

FEATURING Timothy P. Hughes
  • 166 views
  • October 16, 2019
  • 1
19:12

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Management of Advanced Phase CML: Treatment Options for Accelerated, Blast, and Lymphoblastic Phase Disease

FEATURING Elias Jabbour
  • 26 views
  • October 16, 2019
14:57

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Where do Immunotherapies Fit in the Treatment Landscape of ALL?

FEATURING Partow Kebriaei
  • 73 views
  • October 16, 2019
14:33

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How To Cure The Very High Risk Childhood ALL? Dasatinib vs. Imatinib & Combination Venetoclax and Navitoclax in R/R

FEATURING Ching-Hon Pui
  • 13 views
  • October 16, 2019
15:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Future of Frontline ALL in Adults: Complex Biological Work up and Drug Profiling Driven Immunostrategies/Targeted Therapies, Chemo-Free Approach, and CAR T

FEATURING Nicolas Boissel
  • 21 views
  • October 16, 2019
14:54

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Harnessing the Immune System for Treating AML: Targeting CD33 and IL-3, Bispecifiic Antibodies, Mechanisms of Action, Checkpoint Inhibitors in Clinical Trials

FEATURING Farhad Ravandi
  • 122 views
  • October 16, 2019
15:26

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

IDH Inhibitor Therapy in AML: Ivosidenib & Enasidenib Mono and Combination Therapy

FEATURING Courtney D. DiNardo
  • 341 views
  • October 16, 2019
10:11

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Manipulating Microenvironment to Overcome Chemotherapy Resistance in R/R AML With Uproleselan, E-Selectin Antagonist

FEATURING Daniel J. DeAngelo
  • 17 views
  • October 17, 2019
22:31

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Identification and Management of Patients with Polycythemia Vera and Myelofibrosis Treated With Ruxolitinib, and How to Improve Their Outcomes

FEATURING Srdan Verstovsek
  • 37 views
  • October 17, 2019
15:43

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Combination Approaches With Ruxolitinib in Primary Myelofibrosis - When is More Treatment Better?

FEATURING Naveen Pemmaraju
  • 22 views
  • October 17, 2019
13:07

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Identification and Management of Ruxolitinib Failure in Myelofibrosis: What Are Other JAK Inhibitor Options?

FEATURING Lucia Masarova
  • 62 views
  • October 17, 2019
10:24

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treatment Options, Novel Agents, and Approaches

FEATURING Kieron Dunleavy
  • 118 views
  • October 17, 2019
  • 1
13:26

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from the CAVALLI Trial, ctDNA Levels as a Promising MRD Detection Method

FEATURING Andrew Zelenetz
  • 90 views
  • October 17, 2019
11:13

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin Is Too Much and the Frontline Brentuximab Vedotin Options

FEATURING Alison Moskowitz
  • 183 views
  • October 17, 2019
  • 1
31:49

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

From CHIP, ICUS, and CCUS to Myelodysplastic Syndromes: Disease States and Tet2-Deficiency Mice Model

FEATURING Lucy Godley
  • 35 views
  • October 17, 2019
20:22

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Lower Risk Myelodysplastic Syndromes Management: Overview of the Current Treatment Options

FEATURING Rami Komrokji
  • 35 views
  • October 17, 2019
25:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Higher Risk Myelodysplastic Syndromes Management: Overview of the Current Treatment Options

FEATURING Valeria Santini
  • 26 views
  • October 17, 2019
09:54

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal and How Do We Get There - Is RVD Good Enough?

FEATURING Amrita Krishnan
  • 147 views
  • October 17, 2019
  • 1
12:16

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment

FEATURING Meletios Dimopoulos
  • 406 views
  • October 17, 2019
  • 3
17:13

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Epigenetic Mechanisms in CLL: Inter- and Intra-Patient Heterogeneity, Early and Late Clones, Dynamics and Spatial Heterogeneity, Implications for Diagnostics and Clinical Trial Design

FEATURING Davide Rossi
  • 18 views
  • October 17, 2019
19:03

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Mechanisms of Resistance in CLL to Targeted Agents: Could We Use These Mutations to Identify Patients Likely to Relapse?

FEATURING Paolo Ghia
  • 68 views
  • October 17, 2019
18:11

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Genomic Complexity of CLL: Complex Karyotype, Cytogenetic Complexity, TP53 Mutation, IGHV, and Whole-Genome Sequencing

FEATURING Richard Rosenquist Brandell
  • 26 views
  • November 5, 2019